The invention describes a novel system for identifying optimized gRNAs for use in CRISPR/Cas9 genome editing platforms. The invention allows for the determination of specific gene alterations rendered by a particular gRNA, thereby permitting the generation of optimized gRNA libraries.

Provided herein are novel .sup.10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.

A method for producing a protein is provided. An objective protein is produced by culturing Talaromyces cellulolyticus having an objective protein-producing ability, which has been modified so that the activity of a YscB protein is reduced, in a culture medium.

Provided herein, in some aspects, are methods and compositions for cell-free production of ribonucleic acid.

The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a Cetuximab-like protein (CLP) by a subject that is administered the agent, therapy or treatment. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition that may benefit from reducing the DNA synthesis of genes that regulate cellular growth and proliferation.

The present disclosure provides systems and methods for transposing a cargo nucleotide sequence to a target nucleic acid site. These systems and methods may comprise a first double-stranded nucleic acid comprising the cargo nucleotide sequence, wherein the cargo nucleotide sequence is configured to interact with a recombinase complex, a cas effector complex comprising a cas effector and at least one engineered guide polynucleotide configured to hybridize to the target nucleic acid site, and the recombinase complex wherein said recombinase complex is configured to recruit the cargo nucleotide to the target nucleic acid site.

The present invention relates to novel endolysin polypeptides or fragments thereof which possess antimicrobial activity, preferably antibacterial activity against Clostridium perfringens. The invention also relates to a nucleic acid molecule encoding the endolysin polypeptide or fragment, a recombinant polynucleotide expression vector comprising such a nucleic acid molecule, as well as a host cell comprising such a nucleic acid molecule or comprising such a recombinant polynucleotide expression vector. The invention also relates to compositions and foodstuffs comprising the endolysin polypeptides or fragments and uses thereof in the treatment of diseases or disorders in animals.

The present disclosure provides, among other things, helper-dependent adenoviral serotype 35 (Ad35) vectors. In various embodiments, helper-dependent Ad35 vectors can be used to deliver a therapeutic payload to a subject in need thereof. Exemplary payloads can encode replacement proteins, antibodies, CARs, TCRs, small RNAs, and genome editing systems. In certain embodiments, a helper-dependent Ad35 vector is engineered for integration of a payload into a host cell genome. The present disclosure further includes methods of gene therapy that include administration of a helper-dependent Ad35 vector to a subject in need thereof.

Disclosed are methods of producing single cut precursor microRNA (pre-miRNA) in a host cell from a primary microRNA (pri-miRNA). Also disclosed are method of increasing production levels of single cut precursor microRNA (pre-miRNA) and decreasing production levels of double cut precursor microRNA (pre-miRNA) in a host cell from a primary microRNA (pri-miRNA); a method of decreasing production levels of single cut precursor microRNA (pre-miRNA) and increasing production of double cut precursor microRNA (pre-miRNA) in a host cell from a primary microRNA (pri-miRNA); a method of modulating expression levels of microRNA (miRNA) in a host cell; a method of modulating expression levels of microRNA (miRNA) in a subject; a method of treating a disease in a subject. Also disclosed herein is a genetically modified primary microRNA (pri-miRNA).